Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK159
- Development stage
- Phase 1
- Lead developer
- Asahi Kasei
- Modality
- Peptides
- Administration
- Transdermal
01
Overview
AK159 is a transdermal formulation of teriparatide acetate, developed by Asahi Kasei Pharma Corporation. Teriparatide is a recombinant human parathyroid hormone (1-34) that acts as an anabolic agent for bone, primarily indicated for the treatment of osteoporosis. This formulation aims to provide an alternative route of administration for teriparatide.
- Other names
- transdermal teriparatideteriparatide patchteriparatide microneedle patch
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on AK159.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK159.